Study Identifies Potential Therapeutic Strategy to Prevent Complications from Sickle Cell Disease

Authorship: In addition to Stowell, Mass General Brigham authors include Connie M. Arthur, and Ryan P. Jajosky. Additional authors include Satheesh Chonat, Jayre A. Jones, Seema R. Patel, William M. Briones, Michelle L. Schoettler, Maya Maarouf, Lauren A. Jeffers, Olufolake Adisa, Fang Tan, Earl Fields, Morgan S. Sterling, Hans Verkerke, Sara H. Graciaa, Elisabetta M. Foppiani, Ross M. Fasano, Patricia E. Zerra, Yongzhi Qiu, Wilbur A. Lam, Solomon F. Ofori-Acquah, Michael Koval, Clinton H. Joiner, and David R. Archer.

Disclosures: Chonat discloses advisory and consultancy relationships with Agios, Alexion, Amgen, Roche/Genentech, and Takeda, and investigator-initiated research with Alexion, Global Blood Therapeutics/Pfizer, and Novartis. Schoettler has consulted for Alexion and Omeros. Adisa is employed by Novartis Pharmaceuticals. Fasano serves on medical advisory boards for Global Blood Therapeutics, Forma Therapeutics, and Cerus Corporation, and receives research funding from Forma Therapeutics and Cerus, and consults for REDSIV-Pediatric funded by the NIH/NHLBI. Archer has received research support from Agios, DISC Medicine, and Pfizer. Stowell has consulted for Novartis, Cellics, Argenex, and Alexion, research funding from Alexion, and has received speaking honoraria from Grifols.

Funding: This study was funded in part by the National Institutes of Health (U01 HL117721-01, K12HD072245, R21EB028519, 5R01HL163637, F31HL149323, 5R01HL165975, 5R01HL135575, 5P01HL171803), and the American Society of Hematology (Scholar award).

Continue Reading